



NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the October 2012 NCCN Trends™ Survey, which focused on Chronic Myelogenous Leukemia. This survey was sent to U.S. and International users of NCCN.org.

DEMOGRAPHICS


Distribution of Respondent Types (n = 648)



Q1. Do you treat patients with chronic myelogenous leukemia (CML)? (n = 647)




Q2. Would you consider the following results an 'Optimal Response' at a 3-month evaluation point in patients with CML?



Q2. Would you consider the following results an 'Optimal Response' at a 3-month evaluation point in patients with CML?

By Geography †

■ Yes
 ■ No
 ■ Not sure




Continued on Page 5

†Note: Percentages may not total 100 because of rounding.
 © National Comprehensive Cancer Network, Inc. 2012. All Rights Reserved. For Personal Use Only.
 This report may not be reproduced or distributed beyond personal use in any form without the express written permission of NCCN.

Q2. Would you consider the following results an 'Optimal Response' at a 3-month evaluation point in patients with CML?


By Geography †



†Note: Percentages may not total 100 because of rounding.
 © National Comprehensive Cancer Network, Inc. 2012. All Rights Reserved. For Personal Use Only.
 This report may not be reproduced or distributed beyond personal use in any form without the express written permission of NCCN.

Q2. Would you consider the following results an 'Optimal Response' at a 3-month evaluation point in patients with CML?

By Practice Size †



Continued on Page 7


†Note: Percentages may not total 100 because of rounding.
 © National Comprehensive Cancer Network, Inc. 2012. All Rights Reserved. For Personal Use Only.
 This report may not be reproduced or distributed beyond personal use in any form without the express written permission of NCCN.

Q2. Would you consider the following results an 'Optimal Response' at a 3-month evaluation point in patients with CML?

By Practice Size †

■ Yes
 ■ No
 ■ Not sure


Continued from Page 6



†Note: Percentages may not total 100 because of rounding.
 © National Comprehensive Cancer Network, Inc. 2012. All Rights Reserved. For Personal Use Only.
 This report may not be reproduced or distributed beyond personal use in any form without the express written permission of NCCN.

Q2. Would you consider the following results an 'Optimal Response' at a 3-month evaluation point in patients with CML?

By Practice Setting




Continued on Page 9

Q2. Would you consider the following results an 'Optimal Response' at a 3-month evaluation point in patients with CML?

By Practice Setting


Continued from Page 8

- Yes
- No
- Not sure



Q2. Would you consider the following results an 'Optimal Response' at a 3-month evaluation point in patients with CML?

By Specialty †




Continued on Page 11

Q2. Would you consider the following results an 'Optimal Response' at a 3-month evaluation point in patients with CML?

By Specialty †


■ Yes
 ■ No
 ■ Not sure

Continued from Page 10



†Note: Percentages may not total 100 because of rounding.

Q3. With the following results, what treatment strategy would you recommend at the 12-month evaluation point for a patient with CML? †




†Note: Percentages may not total 100 because of rounding.

Q3. With the following results, what treatment strategy would you recommend at the 12-month evaluation point for a patient with CML?

By Geography †

- Continue the current dose of therapy
- Increase the dose of current therapy
- Switch the patient to alternate therapy
- Not sure



Continued on Page 14


†Note: Percentages may not total 100 because of rounding.
 © National Comprehensive Cancer Network, Inc. 2012, All Rights Reserved. For Personal Use Only.
 This report may not be reproduced or distributed beyond personal use in any form without the express written permission of NCCN.

Q3. With the following results, what treatment strategy would you recommend at the 12-month evaluation point for a patient with CML?

By Geography †

- Continue the current dose of therapy
- Increase the dose of current therapy
- Switch the patient to alternate therapy
- Not sure

Continued from Page 13




†Note: Percentages may not total 100 because of rounding.

Q3. With the following results, what treatment strategy would you recommend at the 12-month evaluation point for a patient with CML?

By Practice Size †

- Continue the current dose of therapy
- Increase the dose of current therapy
- Switch the patient to alternate therapy
- Not sure




†Note: Percentages may not total 100 because of rounding.

Q3. With the following results, what treatment strategy would you recommend at the 12-month evaluation point for a patient with CML?

By Practice Setting †

- Continue the current dose of therapy
- Increase the dose of current therapy
- Switch the patient to alternate therapy
- Not sure




†Note: Percentages may not total 100 because of rounding.

Q3. With the following results, what treatment strategy would you recommend at the 12-month evaluation point for a patient with CML?

By Specialty †

- Continue the current dose of therapy
- Increase the dose of current therapy
- Switch the patient to alternate therapy
- Not sure



Continued on Page 18


†Note: Percentages may not total 100 because of rounding.

Q3. With the following results, what treatment strategy would you recommend at the 12-month evaluation point for a patient with CML?

By Specialty †

- Continue the current dose of therapy
- Increase the dose of current therapy
- Switch the patient to alternate therapy
- Not sure

Continued from Page 17



†Note: Percentages may not total 100 because of rounding.

NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Senior Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.com - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.